Current thinking on the management of the acromegalic patient

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 4, 2007, Pages 311-316

  Katznelson, Laurence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Growth hormone; Primary medical therapy; Radiosurgery; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; BIOLOGICAL MARKER; BROMOCRIPTINE; CABERGOLINE; GLUCOSE; GROWTH HORMONE; LIPID; NITROUS OXIDE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ACROMEGALY; ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GAMMA KNIFE RADIOSURGERY; GLUCOSE HOMEOSTASIS; GROWTH HORMONE RELEASE; HUMAN; LOW DRUG DOSE; MORTALITY; REVIEW; TRANSSPHENOIDAL SURGERY; UNSPECIFIED SIDE EFFECT;

ACROMEGALY; DOPAMINE AGONISTS; HORMONES; HUMANS; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN;

EID: 34447577819     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32816e06cc     Document Type: Review

References (50)

1. Alexander L, Appleton D, Hall R, et al. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980; 12:71-79.
2. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25:102-152.
3. Katznelson L. Diagnosis and treatment of acromegaly. Growth Horm IGF Res 2005; 15 (Suppl A):A31-A35.
4. Melmed S. Acromegaly. N Engl J Med 1990; 322:966-977.
5. Sze L, Schmid C, Bloch KE, et al. Effect of transsphenoidal surgery on sleep apnoea in acromegaly. Eur J Endocrinol 2007; 156:321-329.
6. Grunstein RR, Ho KY, Sullivan CE. Sleep apnea in acromegaly. Ann Intern Med 1991; 115:527-532.
7. Matano Y, Okada T, Suzuki A, et al. Risk of colorectal neoplasm in patients with acromegaly and its relationship with serum growth hormone levels. Am J Gastroenterol 2005; 100:1154-1160.
8. Delhougne B, Deneux C, Abs R, et al. The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. J Clin Endocrinol Metab 1995; 80:3223-3226.
9. Jenkins PJ. Acromegaly and cancer. Horm Res 2004; 62 (Suppl 1):108-115.
10. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-518.
11. Ron E, Gridley G, Hrubec Z, et al. Acromegaly and gastrointestinal cancer. Cancer 1991; 68:1673-1677.
12. Colao A, Marzullo P, Ferone D, et al. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 2000; 85:3132-3140.
13. Colao A, Vitale G, Pivonello R, et al. The heart: an end-organ of GH action. Eur J Endocrinol 2004; 151 (Suppl 1):S93-S101.
14. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992; 21:597-614.
15. Vitale G, Pivonello R, Auriemma RS, et al. Hypertension in acromegaly and in the normal population: prevalence and determinants. Clin Endocrinol (Oxf) 2005; 63:470-476.
16. Arosio M, Sartore G, Rossi CM, et al. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000; 151:551-557.
17. Hekimsoy Z, Ozmen B, Ulusoy S. Homocysteine levels in acromegaly patients. Neuro Endocrinol Lett 2005; 26:811-814.
18. Ronconi V, Giacchetti G, Mariniello B, et al. Reduced nitric oxide levels in acromegaly: cardiovascular implications. Blood Press 2005; 14:227-232.
19. Ronchi CL, Varca V, Beck-Peccoz P, et al. Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. J Clin Endocrinol Metab 2006; 91:121-128. An excellent prospective study on the effects of somatostatin analogs on cardiovascular risk factors. This study, excluding radiation-treated subjects, is controlled and demonstrates the variable effects of somatostatin analogs on glucose homeostasis over a 6-year follow-up.
20. Colao A, Pivonello R, Auriemma RS, et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 2006; 154:467-477. This study demonstrates the benefit of pegvisomant on cardiovascular risk profiles.
21. Mishra M, Durrington P, Mackness M, et al. The effect of atorvastatin on serum lipoproteins in acromegaly. Clin Endocrinol (Oxf) 2005; 62:650-655.
22. Bengtsson BA, Eden S, Ernest I, et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 1988; 223:327-335.
23. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004; 89:667-674.
24. Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998; 83:3419-3426.
25. Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004; 151:439-446.
26. Fahlbusch R, Honegger J, Buchfelder M. Surgical management of acromegaly. Endocrinol Metab Clin North Am 1992; 21:669-692.
27. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005; 152:379-387.
28. Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf) 1996; 45:407-413.
29. Biermasz NR, Van Dulken H, Roelfsema F. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly. J Clin Endocrinol Metab 2000; 85:2476-2482.
30. Powell JS, Wardlaw SL, Post KD, Freda PU. Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure. J Clin Endocrinol Metab 2000; 85:2068-2071.
31. Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997; 82:3187-3191.
32. Castinetti F, Taieb D, Kuhn JM, et al. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab 2005; 90:4483-4488.
33. Jezkova J, Marek J, Hana V, et al. Gamma knife radiosurgery for acromegaly - long-term experience. Clin Endocrinol (Oxf) 2006; 64:588-595.
34. Roberts BK, Ouyang DL, Lad SP, et al. Efficacy and safety of CyberKnife radiosurgery for acromegaly. Pituitary 2007; 10:19-25.
35. Landolt AM, Haller D, Lomax N, et al. Stereotactic radiosurgery for recurrent surgically treated acromegaly: comparison with fractionated radiotherapy. J Neurosurg 1998; 88:1002-1008.
36. Freda PU, Katznelson L, Van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005; 90:4465-4473.
37. Katznelson L. Drug insight: primary medical therapy of acromegaly. Nat Clin Pract Endocrinol Metab 2006; 2:109-117; quiz following 117.
38. Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf) 2006; 64:342-351. This study demonstrates efficacy of somatostatin analogs to improve biochemical parameters and induce tumor shrinkage as de-novo, primary therapy.
39. Melmed S, Sternberg R, Cook D, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:4405-4410.
40. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005; 90:1856-1863.
41. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006; 91:2112-2118.
42. Petrossians P, Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005; 152:61-66.
43. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83:374-378.
44. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171-1177.
45. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001; 358:1754-1759.
46. Parkinson C, Burman P, Messig M, Trainer PJ. Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant. J Clin Endocrinol Metab 2007; 92:190-195.
47. Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol 2005; 153:737-740.
48. Feenstra J, De Herder WW, Ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005; 365:1644-1646.
49. Van der Lely AJ, Muller A, Janssen JA, et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 2001; 86:478-481.
50. Schreiber I, Buchfelder M, Droste M, et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 2007; 156:75-82. Large, multicenter follow-up for patients receiving pegvisomant. Useful for assessment of safety risks.